

# GLP-1 Mimetics

## December 2019



It has recently been highlighted that, in some cases, the quantity of GLP-1 mimetics being prescribed exceeds requirements - resulting in waste and negative cost implications. Prescribers are advised to identify all patients currently being treated with a GLP-1 mimetic and ensure that unintended quantities are not mistakenly prescribed, dispensed and charged for.

Prescribers should also review prescribing of GLP-1 mimetics to ensure they are being prescribed in line with NICE guidance (only continue if the person has had a reduction of at least 11 mmol/mol [1.0%] in HbA1c and a weight loss of at least 3% of initial body weight in 6 months). Discontinue treatment if NICE criteria have not been met.

Monthly prescription quantities are generally encouraged to avoid waste and for safety reasons.

Product	Dose	Monthly Quantity to prescribe
Dulaglutide (Trulicity®)	0.75mg once weekly (monotherapy)	<b>1 pack</b> (4 x 0.75mg/0.5ml pre-filled pens)
	1.5mg once weekly (combination therapy)	<b>1 pack</b> (4 x 1.5mg/0.5ml pre-filled pens)
Exenatide (Byetta®)	5mcg twice daily	<b>1 x</b> (5mcg/0.02ml, 1.2ml pre-filled pen)
	10 mcg twice daily	<b>1 x</b> (10mcg/0.04ml, 2.4ml pre-filled pen)
Exenatide prolonged release (Bydureon®)	2mg once weekly	<b>1 pack</b> (4 x 2mg/0.65ml pre-filled injections)
Liraglutide (Victoza®)	0.6mg once daily ( <b>initiation dose</b> )	<b>1 x</b> 6mg/ml pre-filled disposable pen
	1.2 mg once daily	<b>1 pack</b> (2 x 6mg/ml pre-filled disposable pens)
	1.8mg once daily ( <b>non formulary</b> )	<b>1 pack</b> (3 x 6mg/ml pre-filled disposable pens)
Lixisenatide (Lyxumia®)	10 mcg once daily ( <b>initiation dose</b> )	<b>1 x</b> (10mcg/0.2ml pre-filled pen)
	20 mcg once daily	<b>1 pack</b> (2 x 20mcg/0.2ml pre-filled pen)
Semaglutide (Ozempic®)	0.25mg once weekly ( <b>initiation dose</b> )	<b>1 x</b> (0.25 mg/0.19ml, 1.5ml pre-filled pen)
	0.5mg once weekly	<b>1 x</b> (0.5 mg/0.37ml, 1.5ml pre-filled pen)
	1 mg once weekly	<b>1 x</b> (1 mg/0.74ml, 3ml pre-filled pen)

**Prescribers are advised to review all patients currently being treated with a GLP-1 mimetic and:**

- **ensure that the quantities prescribed do not exceed requirements**
- **discontinue treatment if NICE criteria have not been met.**

For further information, please contact the Medicines Management Team on 01254 282087 (BwD) or 01282 644807 (EL)